Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in JapanHiroyoshi Yokoi, Michael D. Dake, Takao Ohki et al.|JACC: Cardiovascular Interventions|2016Cited by 70
Prognostic Impact of Revascularization in Poor-Risk Patients With Critical Limb IschemiaOsamu Iida, Masaaki Uematsu, Mitsuyoshi Takahara et al.|JACC: Cardiovascular Interventions|2017Cited by 52
The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These LesionsOsamu Iida, Hiroki Takahashi, Michiaki Higashitani et al.|JACC: Cardiovascular Interventions|2016Cited by 37
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year ResultsKimihiko Kichikawa, Michael D. Dake, Shigeo Ichihashi et al.|CardioVascular and Interventional Radiology|2018Cited by 30
Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels—Results from the Zilver PTX Japan Post-Market Surveillance StudyStefano Cipollari, Michael D. Dake, Hiroyoshi Yokoi et al.|Journal of Vascular and Interventional Radiology|2017Cited by 18